Introduction
The progress in apoptosis research made in recent years showed the relevance of dysregulation of apoptosis in disease. An excess of apoptosis may result, eg in T cell depletion in HIV infection, neurodegenerative diseases (Alzheimer's disease) or hepatocellular degeneration (Wilson's disease). Impaired apoptosis, however, is frequently observed in cancer which contributes not only to tumorigenesis but is also associated with the development of therapy-refractory and metastatic disease.
The data presented during this meeting provide new insights into the pathways of apoptosis regulation. Novel pathways have been discovered such as the endoplasmic reticulum (ER)-activated apoptosis leading to cleavage and activation of caspase-12 upon an ER stress response. 1 Furthermore, new pathways for the crosstalk between signaling pathways were presented such as activation of mitochondrial apoptosis via cleavage of Bid by caspase-8. 2, 3 In this context, several groups presented evidence that such events may cause a conformational switch in the pro-apoptotic Bax. 4 Thus, the dissection of mitochondrial apoptosis events was a major focus throughout the meeting. This was also emphasized by the novel concept of an imbalanced mitochondrial ATP metabolism as a motor of apoptosis upon IL-3 growth factor withdrawal. Therapeutic applications of apoptosis control were limited to the inhibition of cell death regulators, mostly the caspases, in neurodegenerative disease. Cancer therapy is still focussing on the gene transfer of apoptosis promoters such as p53, mostly by adenoviral vectors. Nevertheless, the elucidation of signal requirements in the pathways depicted below and the increasing knowledge about the biochemistry of apoptosis induction provide the basis for novel therapeutic strategies and for the development of small molecular compounds to activate and restore defective apoptosis signaling pathways in cancer.
Molecular ordering of cell death pathways
Recent discoveries established that multiple distinct signaling pathways regulate apoptosis ( Figure 1 ). Such pathways are activated in general by the formation of a death-inducing signaling complex (DISC). This event is triggered by an apoptosis promoter such as a death ligand. Activation of the DISC results in the early recruitment of inducer caspases (eg caspases-2, -8, -9, -12). These inducer caspases then amplify the apoptosis signal by cleavage and activation of effector caspases (caspases-3, -6, -7) which execute apoptosis by degrading hundreds of regulatory proteins and activation of endonucleases and other proteases. This concept was first described by the group of Peter Krammer (Heidelberg, Germany) in CD95/Fas receptor-mediated apoptosis upon binding of the Fas ligand. 5 A similar complex of (non-homologous) proteins is observed in mitochondrial apoptosis where a DISC is formed by release of mitochondrial factors (cytochrome C, and probably also caspase-9) to the cytoplasm and formation of a complex with cytoplasmic proteins (APAF-1 and other CARD (caspase-activation and recruitment domain) proteins such as ARC (apoptosis repressor with a cARD) and CIPER (CED-3/ICH-1 prodomain homologous, E10-like regulator; identical to bcl-10, mE10) 6, 7 ). This 'mitochondrial' DISC is also designated as 'apoptosome'. Inhibitors of these apoptosis activators may work at any step of these apoptosis signaling cascades. The basic principle of apoptosis promoters acting in a cascade leading to activation of executing enzymes, eg the cysteinyl aspartases (caspases) is evolutionary conserved and can be traced back to archaic organisms such as Cenorhabditis elegans and possibly even simpler organisms such as slime molds (Dictyostelium) and even bacteria. The most prominent of these pathways are activated either by mitochondria (addressed by Jean Claude Martinou (Geneva, Switzerland), Eileen White (Piscataway, USA), and Craig Thompson (Philadelphia, USA)) or the death receptors belonging to the superfamily of TNF receptors (presented by Peter Krammer and Jü rg Tschopp (Epalinges, Switzerland)). Further-
Figure 1
Apoptosis signaling pathways. The basic concept of activation and inhibition of apoptosis signaling cascades can be found in archaic organisms such as C. elegans. The human apoptosis inhibitor Bcl-2 is homologous to ced-9, Bax is homologous to egl-1, Apaf-1 to ced-4, and caspase-3 to ced-3. The activation of a death effector such as Bax or a death receptor leads to the formation of a death-inducing signaling complex and the activation of inducer caspases. Large amounts of Bak localize to the ER. The participation of Bak in the ER apoptosis is, however, hypothetical. CED, C. elegans death gene; ER, endoplasmatic reticulum; UPR, unfolded protein response; SOD, silencer of death domain; FLIP S , short splice variant of Fas-linked inhibitory protein; FLIP L , long splice variant; FADD, Fas-associated death domain. more, evidence was provided that additional death signaling pathways are triggered by organelles different from mitochondria: activation of the endoplasmic reticulum stress pathway induces caspase-12 activation (Jun-Ying Yuan, Boston, USA).
Death receptors
The analysis of such distinct apoptosis pathways led to the definition of death receptor-induced signaling complexes (DISC) and the mitochondrial apoptosome. In the case of the death receptors, binding of a trimeric ligand such as TNF, TRAIL, or the Fas ligand triggers recruitment of adaptor proteins like FADD (TNF and Fas pathway) or RIP and RAIDD (TNF receptor 1) to the death domains of the receptor. 8 These adaptor proteins then recruit procaspases which are thereby activated to the enzymatically active heterotetramers. Caspase-8 is the dominant death receptor-activated caspase and is recruited, eg by the TRAIL receptors (DR3 and DR4), CD95/Fas, and TNF-R1. Caspase-10, which was mainly implicated in TRAIL-mediated death may contribute but is apparently not decisive in TRAIL and Fas signaling (Jü rg Tschopp). In addition, TNF-R1 may recruit Caspase-2 via the RIP and RAIDD adaptor proteins.
While the exact mechanisms how these inducer caspases become cleaved and activated are so far unknown, autocatalysis such as in the case of procaspase-9 (which becomes activated by autocleavage upon multimerization in a complex with APAF-1, see below) has been suggested.
Mitochondria and apoptosis
The mitochondrial activation during apoptosis is inhibited by Bcl-2, Bcl-xL and other apoptosis-preventing members of the Bcl-2 gene family. 9 In contrast, apoptosis-promoting members of this gene family, such as Bax and Bak have been demonstrated to be direct activators of the mitochondria. [9] [10] [11] Loss of Bax is associated with development of therapy resistance in many types of cancer. [12] [13] [14] [15] Members of the Bcl-2 family, the mitochondrial protein cytochrome C and the cytosolic APAF-1 form the so-called mitochondrial apoptosome, also known as mitochondrial DISC. Binding of cytochrome C and (d)ATP to APAF-1 has been shown to trigger conformational changes in APAF-1 leading to the activation of the caspase activation and recruitment domain (CARD) of APAF-1 which then binds procaspase-9.
9,10 Complexing of a minimum of two APAF-1 and two procaspase-9 molecules has been suggested to mediate autocatalysis of procaspase-9 to the active enzyme. Recent evidence suggests that this mechanism is regulated by another CARD-homologous protein, ARC. APAF-1 and ARC were shown to form large multimeric complexes. Such a multimerization might amplify the action of the mitochondrial apoptosome, ie activation of procaspase-9. Another possibility would be that ARC is an inhibitor of the mitochondrial apoptosome. A similar effect could be mediated by another CARDcontaining molecule, CIPER/mE10/bcl-10. 6 This still needs to be clarified. Previous data suggested that Bcl-xL and possibly Bcl-2 act by keeping APAF-1 in an inactive form. Bax was shown in immunoprecipitation experiments to disrupt the interaction between APAF-1 (or the C. elegans homologue ced-4) and Bcl-xL. This, together with cytochrome C release, was suggested to trigger recruitment of procaspase-9. This physical interaction of Bcl-xL with APAF-1, however, appears to be much weaker as could be expected from previous experiments. Thus, the role of Bcl-xL and its homologues appears to be the regulation of cytochrome C release from mitochondria and not the direct regulation of APAF-1 conformational changes.
The mitochondrial apoptosis promoting events can therefore be dissected into distinct steps: The release of cytochrome C from the intimate space between the inner and outer mitochondrial membrane precedes the mitochondrial permeability shift transition, ie the opening of channels, ion fluxes, the acidification of the cytoplasm by the release of protons produced by the respiratory chain. 11 Thus, in neuronal cells (as presented by J-C Martinou) the pro-apoptotic Bax protein can induce cytochrome C release which is associated with (1) shrinking of the mitochondria, (2) clustering of apoptotic mitochondria around the nucleus which (3) cannot be prevented by cyclosporin A or other inhibitors of the mitochondrial permeability transition. These data are in line with the finding that opening of the permeability transition pores of the mitochondria occurs after the cytochrome C release. 4 The apoptosis promoter Bax can form such channels in model systems where recombinant proteins are inserted into artificial membranes (Craig Thompson). Interestingly, preliminary evidence suggests that these channels might be large enough to permeabilize the outer mitochondrial membrane for the release of cytochrome C which has a molecular weight of 15 kDa. In intact cells, the release of cytochrome C coincides with a conformational change of Bax which is revealed by the use of conformation-specific N-terminal antiBax antibodies. 4 It is, however, not yet clear whether this cytochrome C releasing channel is formed by Bax itself or whether Bax is regulating another channel.
This mechanism of permeabilization of mitochondria is similar to some extent to the mechanism of action of bacterial toxins such as colicins (X-ray structure of Bcl-xL suggests structural similarities to diptheria toxin and colicins 16 ): (1) they bind to receptors on the outer membrane, (2) translocate to the periplasmic membrane and (3) undergo a conformational change which mediates (4) channel formation. 16 As presented by Craig Thompson, the mitochondrial apoptosis program seems to be associated with an energy breakdown of the cell during apoptosis induced by growth factor withdrawal in IL-3-dependent cells. Overexpression of IL-3 prevents loss of ATP which would precede biochemical (eg caspase activation and DNA fragmentation) and morphological events by several hours during apoptosis. In the cells induced for apoptosis by IL-3 withdrawal, an increase of creatine kinase activity was observed. This enzyme consumes ATP and transfers the energy to phosphorylated creatine which is retained and stored in the space between the inner and outer mitochondrial membrane. The overexpression of Bcl-xL can prevent the increase of creatine-phosphate and allows release of the creatine-phosphate to the cytosol which leads to the immediate restoration of the ATP pool. Bcl-xL by itself does not form this channel but appears to promote maintenance of the voltage-dependent channels (VDAC) in the open configuration. This model of Bcl-xL regulating the mitochondrial energy equilibrium may also explain other phenomena during apoptosis: an increased electron transfer rate in the oxidative chain in response to the ATP depletion could account for the increase of lipid peroxidation observed during apoptosis. This would explain why some observations in the past attribute an antioxidant effect to Bcl-2. Such an Leukemia increase of lipid peroxidation could, in combination with water influx from the cytosol into the mitochondria via open channels, be responsible for the swelling of mitochondria leading to terminal disruption of the outer mitochondrial membrane during late apoptosis. Thus, apart from their putative role as channel-forming molecules, the role of Bcl-2, BclxL and their apoptosis-preventing homologues could be to maintain pyruvate/lactate (ie redox potential) and pH homeostasis. This would also make sense from an evolutionary point of view since mitochondria can be considered as enslaved and potentially dangerous prokaryotic organisms. Thus, eukaryotes appear to have tamed these parasites and utilized their killing mechanisms to fine tune cellular death programs. This fine-tuning is mediated by the use of pro-and anti-apoptotic Bcl-2 family members. 9 The mitochondrial apoptosis inducing factor, AIF, 10, 17 received surprisingly little attention during this meeting. This factor was described to be released from apoptotic mitochondria and to translocate to the nucleus where it mediates fragmentation of the DNA into high molecular fragments. The action of AIF is caspase-independent. The contribution of AIF in apoptosis induction is not very clear. It is evident that the complete inhibition of caspase activation can inhibit some forms of apoptosis, eg in neurons, while cell death induced by cytostatic drugs or irradiation is only delayed and not completely inhibited in most assay systems. In cells treated with caspase inhibitors, the morphology changes from the typical signs of apoptosis (ie cell shrinking, chromatin condensation, DNA fragmentation into small oligonucleosomal fragments, membrane blebbing, formation of apoptotic bodies etc) to a necrotic phenotype. It was suggested in several presentations that AIF may account for these changes, ie mediates caspaseindependent pathways of apoptosis as originally published.
Endoplasmic reticulum-induced apoptosis
A novel mechanism of apoptosis regulation was presented by Jun Ying Yuan. She showed that caspase-12 mediates an endoplasmic reticulum (ER)-specific apoptosis pathway. 1 This pathway can be activated by the 'unfolded protein response' (UPR) which is observed, eg upon inhibition of protein export from the ER. 18, 19 Caspase-12 belongs to the caspase-1 subfamily and is localized specifically in the ER. Caspase-12 is activated by ER stress apoptotic signals which include disruption of ER calcium homeostasis and accumulation of excess proteins in the ER. Activation of caspase-12 appears to be independent from death receptor signaling and mitochondrial targeted apoptotic signals. In caspase-12 knock-out (k.o.) mice, caspase-12 was shown to be essential for the ER stressinduced apoptosis and these k.o. mice were protected from the lethal effect of tunicamycin-induced ER stress. Tunicamycin inhibits protein glycosylation in the Golgi apparatus and thereby leads to the retention of proteins in the ER, which explains why this compound is used in experimental systems to induce an UPR. Caspase-12 is localized at the cytosolic side of the ER membrane. Oxygen and glucose deprivation in combination induce caspase-12 activation and induction of the Bip/grp78 and grp94 chaperones which are markers for an UPR response while hypoxia alone was not sufficient to induce this condition. Most interestingly, high concentrations of calpain I and II inhibitors (200 M) can inhibit caspase-12 cleavage. The calpain proteases had been implicated for some time in other apoptosis systems such as thymocyte apoptosis. 20 Calpain cleaves Bcl-xL at a site between the BH4 and the BH3 domain (peptide sequence: HLA/D) which is distinct from a caspase-1 and-3 cleavage site located just downstream of the HLAD sequence. Thus calpain may convert (by a caspase-12-dependent mechanism?) Bcl-xL to a pro-apoptotic death module. Another possible activator of the Caspase-12 pathway is Bak, an apoptosis-promoting Bcl-2 homologue, which also localizes to the ER. A direct application for this pathway may be in Alzheimer's disease. Tae-Wan Kim (Charlestown, USA) described that mutated presenilins which are involved in the deposition of amyloid-␤ are responsible for a disturbed calcium homeostasis, ie the capacity charged calcium entry (CCE). The CCE channels mediate extracellular influx of calcium into the cytosol to refill calcium stores. The disruption of CCE may induce an endoplasmic reticulum stress response, the unfolded protein response. This is in line with the finding that neurons from caspase-12 k.o. mice are resistant to amyloid-␤ protein.
The cell cycle and apoptosis
This rapidly evolving and stimulating field of research was introduced by Thierry Soussi (Paris, France) and the groups presenting therapeutic applications of p53 (see below). It is established knowledge that the p53 gene is one of the most commonly inactivated genes in cancer, which may result in an impaired response to therapy and poor clinical prognosis. 21 DNA damage, hypoxia, viral infection or oncogene activation stabilize the p53 protein. While p53 acts as a DNA-binding protein which mediates transcriptional activation of target genes (eg Bax, p21/WAF-1, 14-3-3, Gadd45, IGF-BP-3, PIGs) the expression of other genes may be transcriptionally repressed. The events triggered by p53 such as cell cycle arrest or induction of apoptosis are to some extent cell type specific, which may explain the diversity of observed p53 responses (see below and Figures 2 and 3) . The p53-triggered cell cycle arrest and initiation of DNA repair upon DNA damage by irradiation or chemical mutagenesis may permit the cell to recover from the damage and to survive. Upon failure, the apoptosis pathways also initiated by p53 are executed and the cell dies. Experimental evidence for this model came from the group of Vogelstein, who showed that the knock-out of p21/WAF-1 impaired the ability of such cells to arrest in the cell cycle at the G1 and G2/M checkpoints upon treatment with cytostatic drugs. 22 In contrast, they continued through the cell cycle and became polyploid. The DNA synthesis occurred independently from cell division. In contrast to the p21 proficient cells, these polyploid p21 k.o. cells died by apoptosis. This may explain why p53-inactivated tumor cells
Figure 2
Intron/Exon structure of the INK4a gene locus. Alternative splicing and exon usage leads to expression of two genes from the same gene locus. Both genes are regulated independently by individual promoters. Exon 2 is translated in the p14ARF by the use of an alternative reading frame (ARF).
Figure 3
The p14ARF/p53 signaling pathway. DNA damage or dysregulated activation of cell cycle promoting factors leads to activation of p14ARF. While the expression of the p16 CDKN2/INK4A protein leads to cell cycle arrest in G1, the p14ARF protein mediates degradation of Mdm-2 by the proteasome. Mdm-2 is an inhibitor of p53 which mediates degradation of p53 protein by the proteasome. Inactivation of Mdm-2 therefore increases p53 protein levels which triggers the spectrum of p53 signaling events: transcriptional activation of death pathways, cell cycle arrest in G1 and G2/M, DNA repair and transcriptional repression of survival genes.
are genetically unstable, which in turn may facilitate accumulation of further genetic alterations related to therapy resistance. Such a genetic instability may be due to a loss of Gadd45 activity in p53-inactivated tumors. Evidence therefore comes from experiments in Gadd45 k.o. mice which are highly aneuploid and carry many chromosomal aberrations. 23 Cell cycle arrest at the G1 restriction point is dependent on the induction of the cyclin-dependent kinase inhibitor p21 while the arrest at the G2/M restriction point occurs due to both p21 and a 14-3-3-dependent sequestration of cyclin B2/cdc2 complexes.
P53 may activate transcription-dependent and -independent mechanism of apoptosis. Transcription-dependent events include induction of apoptosis-mediating genes, such as Bax, PIG3 and IGF-BP3, resulting in enhanced protein expression of these factors (Figure 3) . Synergistic effects between the apoptosis promoting transcription factor E2F-1 and p53 may be required to induce p53-dependent apoptosis. Transcription-independent events are still poorly understood but may involve the 53BP2 protein which interacts competitively with p53 and Bcl-2.
Accumulation of p53 is not due to induced p53 gene transcription or mRNA stabilization but is mediated by stabilization of the p53 protein. P53 protein levels are under the control of Mdm-2 (Hdm-2 in humans). Mdm-2 binds to p53 and mediates p53 degradation by the proteasome. Phosphorylation of the amino terminus of p53 disrupts binding of Mdm-2 and reduces p53 destabilization by Mdm-2. Such phosphorylation events are assumed to be mediated via the ATM and the DNA-PK kinases.
Prolongation of p53 half-life and activity is also a mechanism by which oncogenes such as E2F-1 and c-myc induce apoptosis. Under normal circumstances these genes promote cell cycle progression from the G1 phase to the S phase. Their uncoordinated activation may result in cell death instead of cell cycle progression (ie in the lack of concomitant survival signals). This signaling pathway was recently shown to be mediated via the second product of the INK4a gene locus, p14ARF (ARF stands for alternative reading frame, Figure 2 ). 24 The first gene product discovered to be transcribed from the INK4a gene locus was the cell cycle inhibitory cyclin-dependent kinase inhibitor p16
. P16 is known to be induced by DNA damage via p53-independent mechanisms and mediates an arrest at the G1 restriction point of the cell cycle ( Figure 3 ). The second gene product, p14ARF binds to Mdm-2 and promotes the degradation of Mdm-2 via the proteasome. This in turn stabilizes the p53 protein and activates the p53-dependent events of cell cycle arrest and apoptosis ( Figure 3 ). Both genes are regulated by independent promoters and have been shown to be inactivated independently from each other by promoter methylation or concomittantly by chromosomal 9p deletions.
These data also support the hypothesis that impairment of this pathway either by loss of function of p14ARF, p53, or Bax, or a gain of function of Mdm-2 may result in resistance of the tumor cell to cytotoxic therapies.
Interconnecting the signaling pathways
In the past, some confusion existed concerning the involvement of mitochondria in death receptor-mediated apoptosis. In some cells, overexpression of Bcl-2 could inhibit CD95/Fas-induced apoptosis while others were completely unaffected. This led to the definition of 'type 1' and 'type 2' cells. 25 Type 1 cells recruit the death receptorassociated DISC to the death domain of the receptor and induce rapid activation of receptor-associated inducer caspases, such as caspase-8. In contrast, the DISC recruitment in type 2 cells is much less prominent. The main apoptosis-inducing pathway in these type 2 cells is mediated by activation of mitochondrial cytochrome C release and mitochondrial permeability shift transition.
The recent discovery of Bid cleavage by caspase-8 to tBid (truncated Bid) connects the death receptor to the mitochondrial apoptosis pathway. 2, 3 This mechanism allows a crosstalk between death receptor signaling and pathways leading to mitochondrial activation (Figure 4) . The activation of death receptor signaling and DISC recruitment leads to caspase-8-dependent cleavage of Bid which then binds to Bax. This activates Bax to a conformational change of NH 2 -terminal epitopes which coincides with the release of cytochrome C from the mitochondria. 4 On this track, Eileen White presented evidence that tumor necrosis factor (TNF) also activates Bid cleavage, which in turn mediates a conformational change in Bax. The occurrence of this conformationally altered Bax was shown to coincide with cytochrome C release and caspase-9 activation. The major focus of Eileen White's work is on the regulation of adenoviral replication and host-pathogen interaction. In her Leukemia earlier work, she showed that the adenoviral E1b 19 kDa protein acts as an apoptosis preventing Bcl-2 homologue to prolong the viral cycle in adenovirus-infected cells. Here, she presented data showing that TNF-␣ induces an interaction between E1b and Bax leading to the translocation of E1b to mitochondria and binding of E1b to Bax upon treatment with TNF-␣. This coincided with the conformational change of Bax and the cleavage of Bid to tBid. E1b 19 kDa inhibited cytochrome C release, caspase-9 and partially caspase-3 processing while the upstream events, ie caspase-8 cleavage, remained unaffected.
A similar example for signal pathway crosstalk was presented by Jü rg Tschopp and Peter Krammer. Parts of their presentations were dedicated to the phenomenon of T cell apoptosis and the role of cytokine signaling and other costimulatory signals. Co-stimulation by CD28 is known to inhibit T cell apoptosis: peripheral blood T cells induced by crosslinking of both the CD3 signaling complex and CD28 showed a significantly reduced sensitivity to CD95/Fasinduced apoptosis as compared to T cells activated by CD3 crosslinking alone. This was associated with increased expression of cFLIP. The short and the long splice variant of c-FLIP were shown previously to inhibit binding of caspase-8 to FADD in the DISC (FLIP S and FLIP L ) and activation of caspase-8 (FLIP S ). 26 Interestingly, the culture of the T cells in IL-2 containing medium, which is known to increase Fas sensitivity after several days of culture, led to a down-regulation of c-FLIP. Under such culture conditions, a concomittant decrease of Bcl-xL is observed. Thus, the increase of apoptosis sensitivity to activation-induced cell death, eg via the Fas pathway, is regulated both at the level of the death receptorlinked DISC and the mitochondrial apoptosome.
Very similar effects have been observed in B lymphocytes: the activation via the CD40 receptor may prevent B cells from death by apoptosis. This is most impressive in germinal center (GC) B cells which undergo rapid death by apoptosis when cultured in vitro unless they are rescued by crosslinking of the CD40 receptor by CD40 ligand or agonistic antibodies. 27 The contribution of CD95/Fas to the regulation of B cell apoptosis was suggested in the past but is still not clear. 27, 28 Activationinduced cell death by direct triggering of the antigen receptor is clearly independent of the CD95/Fas ligand. 29 Death in the GC may, however, be finely tuned by a balance between survival signals (mediated via the CD40 receptor on B cells and the B cell antigen receptor) and death signals via CD95/Fas. 27 As presented by Thierry Defrance (Lyon, France), GC B cells show a constitutive activation of the CD95/Fas-associated DISC and rapidly activate caspase-8 when isolated and cultured. Signaling through the B cell antigen receptor (BCR) or CD40 could both induce recruitment of FLIP to the DISC. This is in line with the effect of BCR and CD40 signals to inhibit GC B cell apoptosis. Furthermore, this observation suggests that these B cells may have encountered the Fas ligand in vivo, possibly by interaction with GC T cells or follicular dendritic cells.
In addition, Jü rg Tschopp presented evidence for a link between the ras and the Fas pathway: oncogenic H-ras downregulates Fas expression and renders cells of fibroblastic and epitheloid origin resistant to Fas-induced apoptosis. In H-rastransformed cells, Fas mRNA was decreased, which could be counteracted by treatment with the methylation inhibitor azacitidine, suggesting a hypermethylation of the Fas promoter upon ras activation.
Figure 4
Interconnection of death receptor and mitochondrial apoptosis signaling. Activation of death receptors leads to formation of a DISC. In the case of the CD95/Fas receptor, a trimeric Fas ligand binds to the trimerized receptor. This initiates the formation of the DISC: the adaptor molecule FADD is recruited via interaction of the death domains in Fas and FADD. This mediates the recruitment of procaspase-8 to the DISC by interaction of the DED in the caspase-8 pro-domain and FADD. This results (probably by autocatalysis) in cleavage of the pro-enzyme to the active caspase-8 heterotetramer which consists of two small and two large subunits. Caspase-8 cleaves the apoptosis-promoting Bcl-2 homologue Bid to form tBid. tBid has been shown to physically interact with Bax and to mediate a conformational change in the N-terminal portion of the protein. This activation of Bax coincides with cytochrome C release. This is a decisive step in the activation of the apoptosome, ie the mitochondrial DISC: the cytoplasmic APAF-1 binds the cytochrome C and dATP in the loop domain of the part of the molecule which is homologous to ced-4. This leads to recruitment of procaspase-9 to the complex by interaction of the CARD in the pro-domain of procaspase-9 with the CARD domain of APAF-1. Dimerization of APAF-1 is mediated by the WD40 repeats in APAF-1. This leads to autocatalysis of procaspase-9 and cleavage to the active caspase-9 heterotetramer. tBid connects the receptor-mediated apoptosis which is induced by death ligands to the mitochondrial apoptosis signaling pathway which is activated by cytoplasmic signals, eg upon DNA damage. DD, death domain; DED, death effector domain; DISC, death-inducing signaling complex; FADD, Fas-associated death domain; tBid, truncated Bid; CARD, caspaseactivation and recruitment domain.
Therapeutic intervention
Pharmaceutical companies were intrigued by the discovery of the caspases which allowed them to develop specific inhibitors for these apoptosis-executing enzymes. Donald Nicholson (Montreal, Canada) presented recent developments in the major contributions made by his group and collaborators to elucidate substrate specificity of caspases. 30 By the use of combinatorial positional-scanning peptide libraries, subfamilies of caspases were defined on the biochemical level. The understanding of the specific role of each of the caspases has been aided by such (more or less) specific peptide inhibitors. The elucidation of X-ray crystal structures, the biochemistry of cleavage of caspase substrates and the screening of compound libraries led to the development of compounds showing specific inhibition profiles directed against distinct caspases. Multiple pathways for caspase activation and regulatory control of these enzymes by cellular macromolecular inhibitors have been described so far. Diseases characterized by an excess of apoptosis, eg acute and chronic neurodegenerative diseases and -to some extent -cardiac ischemia, may therefore be targets for the therapeutic application of pharmacological inhibitors of caspases. The application of an inhibitor of caspase-3, an effector caspase which mediates the execution of apoptosis in a broad variety of cell types, was presented to efficiently inhibit the acute brain injury during stroke in a mouse model. The brain area surrounding the ischemic perfusion area was shown to be significantly protected from neuronal apoptosis. This was correlated to a major reduction of tissue damage. However, the issue of penetration of the blood-brain barrier of such compounds remains to be addressed and optimized in further detail.
Caspases, however, are to some extent redundant, as presented by Richard Flavell (New Haven, USA). 31 He presented data supporting that the mitochondrial apoptosis pathway is activated via Bid cleavage upon Fas death receptor-mediated apoptosis of liver cells. Surprisingly, caspase-9 and caspase-3 k.o. mice were not protected from the lethal liver destruction by a murine anti-Fas antibody (Jo-2). In contrast, dexamethasone-induced cell death of immature T cells is inhibited in the caspase-9 k.o. mice which underlines the central role of mitochondrial activation in steroid-triggered cell death. In the caspase-3 k.o. mice, however, activation of the executioner caspase-7 was observed. In caspase-9 k.o. mice, caspase-2 and -6 were activated instead. Thus, compensatory caspase pathways may be activated during the execution phase of apoptosis. This may, in turn, have therapeutic implications, ie impair the effect of specific caspase inhibitors in some conditions or cell types.
Nevertheless, the clear-cut experimental evidence from the animal models upon caspase-3 inhibition showing protection of neurons support a therapeutic usefulness of such compounds and clinical trials in stroke treatment are, according to Nicholson, under preparation and may start in the near future.
The inhibition of the CD95/Fas pathway 5 as presented by Peter Krammer and Klaus-Michael Debatin (Ulm, Germany) may also represent a feasible approach to prevent, eg. neurodegeneration, hepatocelluar degeneration (Wilson's disease) or destruction of T lymphocytes during viral infections, such as by HIV.
In cancer, however, apoptosis pathways are frequently impaired. Along these lines, the search for drugs may soon yield new input coming from the regulation of caspases. Nicholson decribed that the short prodomain of the effector caspase-3 proenzyme contains a tripeptide which appears to inhibit activation of the enzyme. Such control switches may be required to prevent apoptosis under physiological conditions. The definition and mapping of these regulatory domains provides the basis for the search of small molecular compounds which may be useful to selectively activate specific caspases and apoptosis pathways (see Figure 1) . The question how non-malignant cells can be saved from killing by such an apoptosis-activating compound remains to be answered.
An approach more applicable to current treatment strategies was presented by Timothy McDonnell and Alan Pollack (from Houston, USA) who both addressed the mechanisms of prostate cancer apoptosis. Development of androgen resistance is one of the major obstacles for the systemic therapy of metastatic prostate cancer. Under physiological conditions, androgen deprivation induces apoptosis in androgen-dependent prostate cancer cells. This is associated with an increased Bax expression and this specific apoptosis pathway can be inhibited by overexpression of Bcl-2. The expression of Bcl-2 is inversely correlated with p53 inactivation. Thus, likewise to the situation in other cancers, the loss of p53 function, eg by mutation, leads to an induction of Bcl-2 levels which may contribute to the chemoresistance of such tumors. In vitro, the introduction of Bax in DU145 prostate cancer cells (which do not express Bax due to a frameshift in the G8 tract of the Bax gene) restores chemosensitivity. Clinical studies suggest that the combination of androgen depletion together with radiotherapy seems to improve the outcome of locally advanced or high risk patients with prostate cancer. In vitro experiments using the androgen-sensitive LNCaP cells showed an Leukemia increased sensitivity of these cells to radiation-induced apoptosis upon androgen depletion. Selecting those patients with an intact androgen response and an intact apoptosis signaling pathway (ie low Bcl-2, high Bax expression, intact p53) might even further improve the response to such a therapeutic strategy.
The modulation of apoptosis by adenoviral p53 gene transfer for the treatment of prostate cancer was presented by Christopher Logothetis (Houston, USA). This group presented clinical data showing feasibility of such a strategy. Expression of the p53 transgene and induction of apoptosis upon in vivo gene transfer were shown. In analogy to other preliminary data on such clinical trials, the clinical efficiency and the treatment protocol (ie gene transfer alone, or in combination with conventional therapy such as chemo-, radio-and hormone-ablation therapy) remain to be established.
A similar approach for the treatment of non-small cell lung cancer (NSCLC) based on adenoviral gene transfer of p53 was presented by Stephen Swisher (Houston, USA). Earlier data from this group showed feasibility, p53 transgene expression and a vector-attributed local tumor reduction upon injection of a p53 retroviral vector into NSCLC tumors. 32 Due to the limitations of non-replicating retroviral vectors, this group now employs adenoviral vectors which show a higher efficiency of gene transfer in vivo, especially when replicating virus is used as gene transfer vector. Most studies, however, show only limited efficacy, even when replicating virus is applied. This led to the combination of adenoviral p53 gene transfer with DNA damaging agents, mainly cisplatinum. 33 The clinical phase I trial performed at the MD Anderson Cancer Center presented here applied local intratumoral injection of a non-replicating adenovirus (Ad)-p53 vector with or without 80 mg/ml 2 cisplatinum in patients with advanced NSCLC. A total of 52 patients were treated and the monthly Ad-p53 injections were performed by bronchoscopic or CT guided intratumoral injection. Ad-p53 doses were escalated from 10 6 logfold to 10 11 plaque forming units (p.f.u.) in subsequent patients. Vector-induced toxicity was minimal in a total of 167 doses. Transient fever occurred in 20% of the patients within 12 to 24 h after treatment. In 27 of 33 evaluable patients (82%) vector DNA was detected by genomic PCR. RT-PCR showed transgene mRNA expression in 19 of 45 patients (42%). Increased apoptosis was observed in post-treatment tumor tissue specimens. Of the 48 clinically evaluable patients, four showed a partial response, 33 showed stable disease and local tumor progression was observed in 11 patients. Although statistically not significant, higher Ad-p53 doses and the addition of cisplatinum seemed to be more efficient. Due to the (limited) tumor response of this approach, a phase II trial by the use of local triple injection of the RPR/INGN 201 Ad-p53 vector in combination with irradiation was designed.
The tumor cell microenvironment and epigenetic changes in the response to therapy
The response to cytotoxic therapies, such as chemotherapy or irradiation, may also be influenced by the tumor cell microenvironment. This may not only be true for these 'conventional' therapies but also for novel therapeutic strategies such as gene transfer of apoptosis promoters, disruption of survival signals by kinase inhibitors as in the case of bcr-abl positive leukemia, or surface receptor directed apoptosis-inducing therapies, eg by anti-CD20 antibodies in B cell lymphoma.
In accordance with a previous report by the groups of John Hickman (Suresnes, France) and Caroline Dive (Manchester, UK), 34 further evidence was presented by Caroline Dive that the response of B cell lymphoma to etoposide-induced apoptosis can be inhibited by cross-linking of the CD40 antigen which leads to an increased expression of the apoptosis preventing Bcl-xL and NF-kB. Thus, the CD40 receptor/ligand interaction may counteract the effects of tumor therapy in situations where T/B cell collaboration takes place or where infiltrating T cells or other cells express the CD40 ligand.
A similar effect is observed in the case of hypoxia. Aggressive tumors often outgrow their blood supply and the resulting hypoxia may be a selective factor for genetic alterations which protect from apoptosis. 35 As outlined by Adrian Harris (Oxford, UK), hypoxia can cause cell death either by necrosis or by apoptosis. Hypoxic cells cover their energy demand by glycolysis which leads to the production of lactic acid and may generate an acidic extracellular microenvironment. This is of potential interest since the provision of enough nutrients and prevention of medium acidification may inhibit hypoxiainduced cell death in vitro. Thus, pathways protecting from low pH may be important for tumor cell survival. Hypoxia leads to the expression of the hypoxia-inducible factor 1␣, HIF-1␣. This occurs by prolongation of HIF-1␣ half-life: under normoxic conditions, HIF-1␣ is degraded by the proteasome via the Von-Hippel-Lindau (VHL) oncoprotein. In hypoxia this is prevented and HIF-1␣ translocates to the nucleus where it interacts with the aryl hydrocarbon nuclear translocator (ARNT) to bind to specific DNA sequences which are designated as hypoxia response elements (HREs). Such target genes are glycolytic enzymes (ie GLUT-1), vascular endothelial growth factor (VGEF), urokinase receptor, and inducible nitric oxide (NO) synthase which shows that many pathways involved in tumor angiogenesis and invasion are regulated by hypoxia. Interestingly, the effects of HIF-1␣ on apoptosis of the tumor cells varies and some groups could not observe an apoptosis promoting effect of HIF-1␣ suggesting a role for the tumor type and the genetic background of the tumor cell with regard to hypoxia-induced apoptosis. Thus, it is not surprising that inactivation of p53 confers resistance to hypoxia-induced apoptosis. Along these lines, HIF-1␣ has been shown to physically interact with wild-type p53 and to stabilize it thereby contributing to the induction of p53 levels upon hypoxic stress. Thus, it is not surprising that dominant negative HIF-1␣ mutants can inibit hypoxia-induced death in neurons. Nevertheless, hypoxia may also induce apoptosis by p53-independent mechanism and HIF-1␣-independent mechanisms are involved in the hypoxia-induced p53 response. Hypoxia also sensitizes for other apoptosis pathways such as c-myc and Fas-mediated apoptosis and can be counteracted by survival signals, eg the IGF-1 and PI3-kinase pathways.
The contribution of Fas ligand to drug-induced apoptosis was addressed by Klaus Michael Debatin (Ulm, Germany). In contrast to the initial report, Fas ligand appears to contribute but does not seem to be the major player in drug-induced cell death. Low drug concentrations may induce Fas liganddependent apoptosis which can be partially blocked by inhibiting CD95/Fas receptor/ligand interaction. Nevertheless, several groups did not observe such an effect when the CD95/Fas pathway was interrupted. In addition to knock-out mice for the CD95/Fas receptor, Caspase-8 k.o. mice and mice overexpressing a dominant-negative FADD adaptor protein mutant 36 did show an intact apoptosis response upon exposure to cytostatic drugs. Thus, apoptosis can be induced by drugs and irradiation in the absence of CD95/Fas receptor and ligand. [36] [37] [38] This may explain why other research groups could not observe a significant contribution of the Fas system to drug-induced cell death. The major signaling pathway for drug-induced cell death seems to be controlled by the mitochondrial apoptosome. The activation of caspase-8 upon exposure to drugs appears in this case downstream of the mitochondrial apoptosome and independent from the CD95/Fas receptor and the Fas ligand. 38 While some reports attribute a participating role of death receptor signaling, 5, 8 it does not appear to play a major role in the cell death response in this kind of cancer treatment.
Challenging the paradigms
Despite all the data fitting well in current hypotheses, ie showing that Bcl-2-like molecules prevent apoptosis and that loss of the apoptosis-promoting Bax impairs cell death programs, there also arise surprising new views as to how the manipulation of cell death may determine disease pathology.
Viral infection has been shown to activate cell death signaling pathways. This, together with the immune response against infected cells, is thought to be essential in keeping the number of infected cells low and to eliminate the viral infection. In consequence, viruses developed evasive strategies to counteract apoptosis. Thus, viral proteins have been discovered which may inhibit every known step of apoptosis induction ranging from the death receptors down to the caspases. In addition, some viruses developed strategies to promote apoptosis in immune-competent cells such as T cell apoptosis and activation of the CD95/Fas pathway by the HTLV-I tax or HIV tat proteins. 39 Using a replication-competent Sindbis viral vector system which induces apoptosis in neurons of the central nervous system (CNS), the group of Marie Hardwick (Baltimore, USA) demonstrated that, as already known, Bcl-2 and Bcl-xL are cleaved by caspases and thereby converted to apoptosis promoters. Furthermore, the apoptosis promoting Bax was shown to protect from the lethal effect of such a cerebral viral infection by the use of Bax k.o. mice. The Bax proficient mice were protected from the lethality of CNS infection while the Bax k.o. mice died. Surprisingly, Bax did not appear to protect the Bax wild-type mice by promoting death of virally infected cells. No reduction of the viral load in the CNS was seen: the virus titers were comparable in the cerebral tissue of both the Bax wild-type and the Bax k.o. mice. Thus, Bax may act as a death preventing factor in neurons under these conditions. These experiments therefore suggest that apoptosis regulators may work under certain circumstances in an unexpected way. Thus, the role for apoptosis regulators should be defined and validated individually for each disease involving apoptosis dysregulation.
Outlook
This was the first joint European/US American meeting in a series of conferences focussing on therapeutic applications of apoptosis manipulation and the relevance of apoptosis dysregulation for disease pathogenesis.
The presentations during the conference gave a good overview about recent developments in basic and translational apoptosis research. Most unfortunately, important novel developments in hematology were completely neglected, eg the impact of fusion gene products such as bcr-abl 40, 41 or PML/RAR 42-44 on disease pathogenesis, classification and treatment of myeloid leukemia. Recent discoveries in B cell lymphoma about the dysregulation of apoptosis regulators (bcl-10/mE10/CIPER, API-2/cIAP-2 6,45-47 ) were also absent. The molecular understanding of these oncogenes provides not only insights into the disease pathogenesis but also yields novel therapeutic strategies such as the development of specific drugs such as kinase inhibitors in bcr-abl-positive leukemia 48 or the renaissance of arsenic (As 2 O 3 ) which, of course, induce apoptosis in leukemic cells. 49, 50 On the same lines, the activation of apoptotis signaling pathways by anticancer drugs and the mechanisms of cytostatic drug resistance due to inactivation of these pathways were only marginally addressed, especially in the case of the novel agents. 48, 50 Despite the high level of interest in this field of apoptosis research, many groups who have contributed significantly in recent years to the understanding of how anticancer drugs activate apoptosis did not attend this meeting.
Research on cell death mechanisms is rapidly progressing and innovative concepts for disease therapy have been developed recently. The molecular elucidation of dysregulation of apoptosis in myeloid leukemia but also in lymphoid malignancies is, in this context, one of the most stimulating fields in cancer research. This research has already allowed for the development of drugs specifically targeting defective signaling mechanisms. The hope is, therefore, that the next conference in this series which will take place 2-6 June in Cape Cod, USA (www.esh.org), specifically addresses these topics and provides us with even more promising data both on apoptosis in disease pathogenesis and therapeutic applications in the field of hematology and oncology.
